GB8804188D0
(en)
*
|
1988-02-23 |
1988-03-23 |
Croda Int Plc |
Pharmaceutical compositions
|
US5407957A
(en)
*
|
1990-02-13 |
1995-04-18 |
Martek Corporation |
Production of docosahexaenoic acid by dinoflagellates
|
DE69004081T2
(de)
*
|
1990-05-23 |
1994-02-10 |
Nestle Sa |
Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
|
GB9012651D0
(en)
*
|
1990-06-06 |
1990-07-25 |
Efamol Holdings |
Essential fatty acid treatment
|
RU2093996C1
(ru)
*
|
1991-01-24 |
1997-10-27 |
Мартек Корпорейшн |
Способ добавления в детскую питательную смесь докозагексановой кислоты и арахидоновой кислоты (варианты) и композиция (варианты)
|
WO1994015464A1
(en)
*
|
1993-01-15 |
1994-07-21 |
Abbott Laboratories |
Structured lipids
|
US20050027004A1
(en)
*
|
1993-06-09 |
2005-02-03 |
Martek Biosciences Corporation |
Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
|
US5411988A
(en)
*
|
1993-10-27 |
1995-05-02 |
Bockow; Barry I. |
Compositions and methods for inhibiting inflammation and adhesion formation
|
WO1997021434A1
(en)
*
|
1995-12-11 |
1997-06-19 |
Inholtra, Inc. |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
US5840715A
(en)
*
|
1995-12-11 |
1998-11-24 |
Inholtra Investment Holdings & Trading, N.V. |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
DE19629433A1
(de)
*
|
1996-07-22 |
1998-01-29 |
Hoechst Ag |
Omega-3-fettsäurenenthaltende Zubereitung aus Mikroorganismen als Prophylaktikum bzw. Therapeutikum gegen parasitäre Erkrankungen beim Tier
|
US5968809A
(en)
*
|
1997-04-11 |
1999-10-19 |
Abbot Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
|
US5972664A
(en)
*
|
1997-04-11 |
1999-10-26 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
|
US6075183A
(en)
*
|
1997-04-11 |
2000-06-13 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
|
US6051754A
(en)
*
|
1997-04-11 |
2000-04-18 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
|
US7745694B1
(en)
|
1997-04-11 |
2010-06-29 |
Monsanto Technology Llc |
Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
|
US6180671B1
(en)
|
1998-03-10 |
2001-01-30 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
|
US6136795A
(en)
*
|
1998-11-18 |
2000-10-24 |
Omni Nutraceuticals, Inc |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
GB9901809D0
(en)
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
WO2001051598A1
(en)
|
2000-01-11 |
2001-07-19 |
Monsanto Technology Llc |
Process for making an enriched mixture of polyunsaturated fatty acid esters
|
ES2386841T3
(es)
*
|
2001-06-18 |
2012-09-03 |
Neptune Technologies & Bioressources Inc. |
Extractos de krill para la prevención y/o el tratamiento de enfermedades cardiovasculares
|
WO2004091603A1
(fr)
*
|
2003-04-07 |
2004-10-28 |
Clinigenetics |
Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
|
US8633247B2
(en)
|
2003-08-11 |
2014-01-21 |
Hill's Pet Nutrition, Inc. |
Method for decreasing cartilage damage in dogs
|
US8633246B2
(en)
*
|
2003-08-11 |
2014-01-21 |
Hill's Pet Nutrition, Inc. |
Omega-3 fatty acids for osteoarthritis
|
US8075910B2
(en)
*
|
2004-05-20 |
2011-12-13 |
Pbm Pharmaceuticals, Inc. |
Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
|
EP1833498B1
(en)
*
|
2004-11-29 |
2010-01-27 |
Unilever PLC |
Oral composition for enhancing skin properties
|
US20060286199A1
(en)
*
|
2005-06-03 |
2006-12-21 |
Marilou Laprise |
Method and composition for increasing omega-3 lipid in milk
|
US8987329B2
(en)
*
|
2006-04-12 |
2015-03-24 |
Conopco, Inc. |
Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
|
ES2562977T3
(es)
*
|
2006-04-12 |
2016-03-09 |
Unilever N.V. |
Composición oral con un efecto antienvejecimiento sobre la piel
|
US20090018186A1
(en)
*
|
2006-09-06 |
2009-01-15 |
The Coca-Cola Company |
Stable beverage products comprising polyunsaturated fatty acid emulsions
|
US20080058418A1
(en)
*
|
2006-09-06 |
2008-03-06 |
The Coca-Cola Company |
Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
|
DE102007055344A1
(de)
*
|
2007-11-19 |
2009-05-20 |
K. D. Pharma Bexbach Gmbh |
Neue Verwendung von Omega-3-Fettsäure(n)
|
WO2010028067A1
(en)
|
2008-09-02 |
2010-03-11 |
Amarin Corporation Plc |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
LT3037089T
(lt)
|
2009-02-10 |
2020-01-10 |
Amarin Pharmaceuticals Ireland Limited |
Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
|
BRPI1009431A2
(pt)
*
|
2009-03-09 |
2016-03-01 |
Pronova Biopharma Norge As |
pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema
|
JP5872453B2
(ja)
|
2009-04-17 |
2016-03-01 |
ナタク ファルマ エセ.エレ. |
フィタン酸含量が低く、ω−3脂肪酸に富む組成物
|
LT3278665T
(lt)
|
2009-04-29 |
2020-12-10 |
Amarin Pharmaceuticals Ireland Limited |
Stabili farmacinė kompozicija ir jos panaudojimo būdai
|
MY173994A
(en)
|
2009-04-29 |
2020-03-03 |
Amarin Corp Plc |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
BRPI1011883A2
(pt)
|
2009-06-15 |
2016-09-13 |
Amarin Pharma Inc |
uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
|
BR112012006692B8
(pt)
|
2009-09-23 |
2021-05-25 |
Amarin Corp Plc |
composição farmacêutica compreendendo um derivado de hidróxi de atorvastatina e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato
|
KR101204748B1
(ko)
*
|
2009-12-17 |
2012-11-26 |
(주) 켐포트 |
고도 불포화 지방산을 고농도로 함유하는 트리글리세라이드 유지의 제조방법
|
WO2011097276A1
(en)
*
|
2010-02-02 |
2011-08-11 |
Martek Biosciences Corporation |
Methods and compositions for treating arthritis with docosahexaenoic acid
|
US20140004186A1
(en)
*
|
2010-09-08 |
2014-01-02 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
NZ778131A
(en)
|
2010-11-29 |
2023-03-31 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
WO2013070735A1
(en)
|
2011-11-07 |
2013-05-16 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
RU2664429C2
(ru)
|
2012-01-06 |
2018-08-17 |
Омтера Фармасьютикалс, Инк. |
Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA
|
JP6307442B2
(ja)
|
2012-01-06 |
2018-04-04 |
アマリン ファーマシューティカルス アイルランド リミテッド |
対象の高感度(hs−crp)のレベルを低下させる組成物および方法
|
JP6173437B2
(ja)
|
2012-05-07 |
2017-08-02 |
オムセラ・ファーマシューティカルズ・インコーポレイテッド |
スタチン及びω−3脂肪酸の組成物
|
DK3815684T3
(da)
|
2012-06-29 |
2024-10-21 |
Amarin Pharmaceuticals Ie Ltd |
Fremgangsmåder til at reducere risikoen for en kardiovaskulær hændelse i en person i statinbehandling
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
US10966951B2
(en)
|
2017-05-19 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
MX2021002553A
(es)
|
2018-09-24 |
2021-04-29 |
Amarin Pharmaceuticals Ie Ltd |
Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
|
WO2022225896A1
(en)
|
2021-04-21 |
2022-10-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|